- Sinovac Biotech ( NASDAQ: SVA ) on Wednesday said its COVID-19 vaccine had been given approval for use in children aged six months to three years in Hong Kong.
- The Health Bureau of the Government of the Hong Kong Special Administrative Region of the People's Republic of China had approved the vaccine, called CoronaVac, based on related clinical studies and studies of vaccination for local children and teens, Sinovac said in a statement .
- SVA said the vaccination dosage for the six months to three years age group will follow the same schedule as that in older children i.e. two doses to be given 28 days apart followed by a third dose at least three months after the second.
- SVA's CoronaVac already had an emergency use approval in Hong Kong for minors and adults above 3 years old since Feb.
- Sinovac ( SVA ) said that as of Aug., its COVID vaccine had been approved for use in children in 14 countries in Latin America, as well as other Asian and African nations.
For further details see:
Sinovac's COVID shot approved for use in children aged 6 months to 3 years in Hong Kong